Trial shows osimertinib plus chemotherapy improves overall survival in EGFR-mutated advanced NSCLC

Published Date: 08 Sep 2025

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A BRAF V600E mutation-positive intrathoracic synovial sarcoma is reported by researchers.

2.

No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer

3.

Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.

4.

An inoperable locally advanced NSCLC trial dubbed "Practice Changing".

5.

CDC Alerts on Dramatic Rise in Human Parvovirus B19


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot